APRE Aprea Therapeutics, Inc.

100

Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]

US | NASDAQ | Stock

Price
$4.45
Decreased by -0.03%
Dollar Volume
69.27 K
ADR%
4.89
Earnings Report Date (estimate)
May 15, 23 (N/A)
Market Cap.
16.61 M
Shares Float
0.00
Shares Outstanding
3.73 M
Beta
0.00
Price / Earnings
-0.05
BPR
1.21 K
20D Range
4.44 5.45
50D Range
0.45 9.90
200D Range
0.30 9.90
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 22 -0.12
Increased by +73.33%
 -0.28
Increased by +204.08%
Aug 11, 22 -4.34
Decreased by -804.17%
 -0.37
Decreased by -2.90 K%
May 16, 22 -0.36
Increased by +21.74%
 -0.38
Increased by +13.85%
Mar 15, 22 -0.36
Increased by +50.68%
 -0.44
Increased by +41.32%
Nov 8, 21 -0.45
Increased by +22.41%
 -0.45
Aug 12, 21 -0.48
Increased by +38.46%
 -0.47
Decreased by -4.53%
May 6, 21 -0.46
Increased by +86.89%
 -0.49
Increased by +12.49%
Mar 16, 21 -0.73
Decreased by -62.22%
 -0.64
Decreased by -21.97%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
 -4.02 M
Increased by +57.42%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
 -98.26 M
Decreased by -858.52%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
 -7.94 M
Increased by +17.91%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
 -7.76 M
Increased by +49.62%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
 -9.45 M
Increased by +23.26%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
 -10.25 M
Increased by +37.37%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
 -9.67 M
Decreased by -2.86%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
 -15.39 M
Decreased by -17.75%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.